Table 1. Demographics and clinical characteristics of patients in study of treatments for West Nile virus central nervous system disease, by treatment arm* .
| Characteristic | Omr-IgG-am, n = 37 | Polygam, n = 12 | Normal saline, n = 13 | Total, n = 62 |
|---|---|---|---|---|
| Race | ||||
| Caucasian/not Hispanic | 24 (64.9) | 10 (83.3) | 11 (84.6) | 45 (72.6) |
| Black/not Hispanic | 2 (5.4) | 0 | 1 (7.7) | 3 (4.8) |
| Hispanic | 8 (21.6) | 1 (8.3) | 1 (7.7) | 10 (16.1) |
| Other |
3 (8.1) |
1 (8.3) |
0 (0) |
4 (6.5) |
| Sex | ||||
| M | 25 (67.6) | 7 (58.3) | 9 (69.2) | 41 (66.1) |
| F |
12 (32.4) |
5 (41.7) |
4 (30.8) |
21 (33.9) |
| Age, y, mean ± SE |
56.2 ± 2.2 |
54.0 ± 4.1 |
58.4 ± 4.8 |
56.2 ± 1.8 |
| Cerebrospinal fluid | ||||
| Leukocytes, cells/µL, mean ± SE (median) | 207.7 ± 40.3 (124) | 187.4 ± 105.5 (58) | 146.6 ± 85.8 (37) | 192.3 ± 35.3 (95.5) |
| % Lymphocytes, mean ± SE (median) |
53.9 ± 5.0 (52.5) |
39.3 ± 10.0 (36.5) |
50.2 ± 11.6 (34) |
50.1 ± 4.3 (43) |
| Time from admission to drug infusion, d,
mean ± SE (median) |
2.9 ± 0.5 (2) |
2.8 ± 0.5 (2.5) |
2.0 ± 0.4 (2) |
2.7 ± 0.3 (2) |
| Disease group and risk factors | ||||
| With encephalitis/myelitis | 25 (64.7) | 9 (75.0) | 11 (84.6) | 44 (71.0) |
| Without encephalitis/myelitis | 12 (32.4) | 3 (25.0) | 2 (15.4) | 17 (27.4) |
| Hematologic malignancy | 1 (8.3) | 0 | 0 | 1 (5.9) |
| Diabetes mellitus | 2 (16.7) | 0 | 0 | 2 (11.8) |
| Bone marrow transplant |
1 (8.3) |
0 |
0 |
1 (5.9) |
| Immunosuppressive medications | 1 (8.3) | 0 | 0 | 1 (5.9) |
*Values are no. (%) patients except as indicated. In comparing Omr-IgG-am with Polygam and Omr-IgG-am with normal saline, no significant differences were identified for characteristics listed in this table (all p values >0.05). Denominators vary according to the number of evaluable patients or assessments.